Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study tests the effectivity and tolerability of treatment with alemtuzumab (MabCampath)
in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or
T-lymphoblastic lymphoma. In Arm A, patients with refractory relapse receive a 2 week
treatment with MabCampath followed by remission evaluation. In case of insufficient response,
treatment with cladribine is added. In Arm B, patients with molecular relapse (minimal
residual disease) receive a 4 week treatment with MabCampath followed by remission
evaluation. In both arms, treatment is continued in case of response for up to two months.